Piper Sandler lifts price targets on Jazz and Teva shares
Piper Sandler raised its price target on Jazz Pharmaceuticals to $330 and on Teva Pharmaceuticals to $56, keeping both at Overweight ratings.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Piper Sandler raised its price target on Jazz Pharmaceuticals shares to $330 per share from $310 and kept its Overweight rating. For Teva Pharmaceuticals, the target was lifted from $44 to $56, and the Overweight rating was also maintained.
The information, which cites Benzinga, was reported by Dow Jones Newswires.
why it matters
Price target revisions reflect analysts' assessment of company prospects and can shape investor sentiment toward pharmaceutical stocks. Such decisions rarely move the broader market on their own, but higher targets alongside an Overweight rating are generally read as a positive signal for the shares.
tags
instruments
on polymarket
sources
- Jazz Pharmaceuticals Price Target Raised to $330.00/Share From $310.00 by Piper Sandler — Dow Jones Newswires, 12 November 2026 at 13:11 UTC
- Teva Pharmaceuticals Price Target Raised to $56.00/Share From $44.00 by Piper Sandler — Dow Jones Newswires, 12 November 2026 at 13:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗